BioNeutral Group, Inc. (OTCBB: BONU) (OTCQB: BONU), today announced that Quip Laboratories (Quip) has made great strides in the ever important product launch process of BioNeutral products for the market segments of laboratory animal research and biomedical research.
Quip Laboratories a leader in sales distribution of cleaning and disinfection solutions to the life science marketplace since 1981 has completed two major elements to its 2014 commercialization strategy of the BioNeutral products. First, YGIENE 206 and OGIENE Odor Eliminator product training was completed during the annual "QUIP University" Sales meeting in March and second, QUIP has featured YGIENE 206 in its recent market awareness campaign of April 4, 2014.
The "QUIP University" Sales training was completed during the week of March 17th. YGIENE 206 and OGIENE Odor Eliminator product training was conducted by the QUIP marketing team and guest faculty members from BioNeutral. With all of QUIP's Sales professionals fully trained, the BioNeutral products are obtaining broad exposure to the Biomedical Research and Lab Animal Science markets nationally. "The excitement level and depth of questions surrounding BioNeutral's combinational chemistry during the training was impressive," commented Dr. Andy Kielbania, Chief Science Officer for BioNeutral. "It is clear that both YGIENE and OGIENE will be introduced to this highly technical marketplace by sales professionals that have the credibility and depth of knowledge to do it right."
QUIP Laboratories featured the YGIENE 206 Sterilant/Disinfectant in its recent "Biosafety Update" product awareness campaign on April 4, 2014. QUIP is utilizing direct email to generate immediate exposure and rapid interest, nationally, for YGIENE 206 as one of its exciting new products for 2014.
"YGIENE 206 has already been enthusiastically received by our clients in the Biomedical Research and Laboratory Animal Research sectors," reports Nick Hidell, product manager for QUIP, "and we're not surprised, given how well the product fits into our product portfolio. The response, from both current and prospective clients, to the product's consistent efficacy, ready-to-use accessibility and long shelf-life, is exciting and indicates that we are well-positioned to gain rapid share among clients in the market sectors we serve." Hidell concluded by saying that, "we see this as both a market disrupter, and game changer, in terms of client acquisition across several sectors we're targeting for expansion in 2014."
About Quip Laboratories, Inc.
Based in Wilmington, DE and founded in 1981, Quip Laboratories focuses on providing sanitation solutions to Life Science and Food Processing sectors. Their state-of-the-art manufacturing facility produces proprietary chemicals that have enabled the company to achieve a leadership position in the markets served. Featuring in-house research and development, production, quality control and sales and marketing, Quip provides a "total-systems" approach to providing efficient and eco-gentle environment hygiene. Find Quip atwww.quiplabs.com.
About BioNeutral Group, Inc.
Headquartered in Newark, New Jersey, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, YGIENE™ and OGIENE™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the YGIENE™ brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to YGIENE-206. BioNeutral's antimicrobial formulations will be marketed under the brand name YGIENE™ and are available for sale in the United States.
CONTACT FOR THE COMPANY:
Mark Lowenthal
CEO
BioNeutral Group, Inc.
+1-973-577-8003
SOURCE: BioNeutral Group, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
BONU_4-17-2014_ELS_ETL.docx
07560116042014-1448951574BONU_4-17-2014_ELS_ETL.001.png
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment